Cabaletta Bio, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology issuer developing engineered T cell therapies for autoimmune diseases. Form 8-K reports cover operating and financial results, corporate presentations, material agreements, and clinical or regulatory updates involving rese-cel and the RESET clinical development program.
Proxy materials describe annual meeting voting matters and governance for holders of Cabaletta Bio common stock. The filing record also identifies the company’s registered common stock, capital-structure disclosures, risk-oriented forward-looking statements, and formal material-event reporting tied to its cell-therapy development and manufacturing strategy.
Cabaletta Bio, Inc. is selling 51,725,000 shares of common stock at $2.90 per share in an underwritten public offering. Gross proceeds are expected to be about $150 million, with estimated net proceeds of approximately $141 million after underwriting discounts and expenses.
As of March 31, 2026, Cabaletta held about $117 million in cash and cash equivalents. The company plans to use the new capital with existing cash mainly to expand clinical development and manufacturing for its CD19 CAR-T candidate rese-cel, and now believes it can fund operations into mid‑2027.
Cabaletta Bio is conducting a primary offering of 51,725,000 shares of its common stock at $2.90 per share. The offering’s public offering price implies gross proceeds of $150,002,500 and expected net proceeds to the company of approximately $141,002,350.
Delivery is expected on or about May 5, 2026. Shares outstanding used for post-offering calculations were 100,479,323 as of December 31, 2025. The company states the net proceeds, together with existing cash and cash equivalents, are intended to fund expanded clinical development and manufacturing readiness and are expected to fund operations into mid-2027.
Cabaletta Bio filed a current report describing plans to present new clinical and translational data from four refractory pemphigus vulgaris patients treated with rese-cel in its RESET-PV trial. These patients received the lowest rese-cel dose without preconditioning chemotherapy and had 24–36 weeks of follow-up as of an April 2, 2026 data cut.
The company will share these data at the ASGCT 2026 Annual Meeting on May 14, 2026. Cabaletta also highlights broader development plans for rese-cel across several autoimmune diseases and notes it plans to add a new dose-escalation cohort to the RESET-SLE trial, with initial no-preconditioning dose data anticipated in the first half of 2026.
Cabaletta Bio, Inc. is asking stockholders to approve six proposals at its June 9, 2026 virtual annual meeting. Items include electing two Class I directors, ratifying Ernst & Young as auditor, amending the 2019 stock plan’s evergreen formula, and doubling authorized common shares from 300,000,000 to 600,000,000.
The company notes that its Form 10‑K disclosed conditions raising substantial doubt about its ability to continue as a going concern and highlights the need for additional capital. Stockholders will also vote on a non‑binding say‑on‑pay resolution and an adjournment proposal that would allow extra time to solicit votes if key items initially fall short.
Cabaletta Bio, Inc. is asking stockholders to approve six proposals at its June 9, 2026 virtual annual meeting. Items include electing two Class I directors, ratifying Ernst & Young as auditor, amending the 2019 stock plan’s evergreen formula, and doubling authorized common shares from 300,000,000 to 600,000,000.
The company notes that its Form 10‑K disclosed conditions raising substantial doubt about its ability to continue as a going concern and highlights the need for additional capital. Stockholders will also vote on a non‑binding say‑on‑pay resolution and an adjournment proposal that would allow extra time to solicit votes if key items initially fall short.
Cabaletta Bio, Inc. updated its corporate presentation highlighting progress of rese-cel (CABA-201), a CD19 CAR T cell therapy being developed for multiple autoimmune diseases. The company outlines Phase 1/2 data in myositis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), myasthenia gravis (MG) and pemphigus vulgaris (PV).
Early results show immunomodulator-free clinical responses in dermatomyositis and antisynthetase syndrome using a single weight-based dose, with patients achieving meaningful Total Improvement Score responses while tapering or stopping steroids. In SLE, SSc and MG, patients with active, refractory disease showed improvements in validated disease scores and reductions in autoantibodies after discontinuing multiple prior therapies.
The presentation emphasizes a safety profile that supports outpatient administration, with low rates and delayed onset of cytokine release syndrome and rare neurotoxicity across the first 40 rese-cel–treated autoimmune patients. Cabaletta also details an automation strategy with Cellares and exploration of no-preconditioning regimens aimed at scaling manufacturing, reducing cost of goods and expanding access across high-need autoimmune indications.
Cabaletta Bio, Inc. is soliciting proxies for its virtual 2026 Annual Meeting to be held June 9, 2026, with a record date of April 20, 2026. The board is asking shareholders to elect two Class I directors, ratify Ernst & Young as auditor, approve an amendment to the 2019 Stock Option and Incentive Plan to include pre-funded warrants in its evergreen calculation, and approve a charter amendment to increase authorized common shares from 300,000,000 to 600,000,000. The proxy materials and the 2025 Annual Report will be available at the company web portal and the SEC site. Voting mechanics, broker vote effects, and quorum rules are described in the proxy statement.
Cabaletta Bio presents a late clinical-stage pipeline built around rese-cel, a CD19 CAR T therapy aimed at delivering one-time, potentially durable treatment for multiple autoimmune diseases. The company is running parallel Phase 1/2 RESET trials in SLE, myositis, systemic sclerosis, generalized myasthenia gravis and pemphigus vulgaris, and has already initiated a registrational DM/ASyS cohort in myositis with a planned BLA submission in 2027.
Rese-cel has received multiple FDA designations, including Fast Track, Orphan Drug, Rare Pediatric Disease and RMAT across several indications, and Cabaletta is building a multi-partner manufacturing network with Oxford Biomedica, Minaris, Lonza and Cellares to scale supply, including automated production. As of June 30, 2025, non-affiliate market value was about $137 million, with 111,322,671 common shares outstanding as of March 19, 2026. Management discloses substantial doubt about the company’s ability to continue as a going concern beyond its current cash runway into the fourth quarter of 2026 without additional funding.
Cabaletta Bio reported fourth quarter and full year 2025 results and highlighted rapid progress of its CD19 CAR-T candidate rese-cel across multiple autoimmune diseases. R&D expenses rose to $36.2M for the quarter and $142.7M for the year, reflecting expansion of the RESET clinical program. The company ended December 31, 2025 with $133.6M in cash, cash equivalents and short-term investments and subsequently raised an additional $30.0M via ATM sales and warrant exercises. Management believes this cash position can fund the operating plan into the fourth quarter of 2026.
Cabaletta outlined a 17-patient single-arm registrational myositis cohort targeting a potential 2027 BLA submission, reported favorable early safety data in the first 40 rese-cel patients with preconditioning, and detailed an expanding Phase 1/2 dataset in systemic lupus erythematosus, systemic sclerosis and myasthenia gravis with complete Phase 1/2 data expected in the first half of 2026. The company is also advancing a no-preconditioning strategy, automated manufacturing with Cellares’ Cell Shuttle and plans multiple readouts in 2026 that are intended to support FDA discussions on registrational designs across indications.
Cabaletta Bio, Inc. reported that Chief Business Officer Arun Das received a grant of stock options. The award covers 175,000 options to buy Cabaletta Bio common stock at an exercise price of $0.00 per share, representing a compensatory equity grant rather than a market purchase.
According to the vesting terms, 25% of the shares underlying this option vest and become exercisable on March 1, 2027. The remaining options vest in twelve substantially equal quarterly installments after that date, as long as he continues in service through each vesting date.